Association Between Preserved Ratio Impaired Spirometry and Clinical Outcomes in US Adults.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN: 1538-3598 (Electronic) Linking ISSN: 00987484 NLM ISO Abbreviation: JAMA Subsets: MEDLINE
    • Publication Information:
      Original Publication: Chicago : American Medical Association, 1960-
    • Subject Terms:
    • Abstract:
      Importance: Chronic lung diseases are a leading cause of morbidity and mortality. Unlike chronic obstructive pulmonary disease, clinical outcomes associated with proportional reductions in expiratory lung volumes without obstruction, otherwise known as preserved ratio impaired spirometry (PRISm), are poorly understood.
      Objective: To examine the prevalence, correlates, and clinical outcomes associated with PRISm in US adults.
      Design, Setting, and Participants: The National Heart, Lung, and Blood Institute (NHLBI) Pooled Cohorts Study was a retrospective study with harmonized pooled data from 9 US general population-based cohorts (enrollment, 65 251 participants aged 18 to 102 years of whom 53 701 participants had valid baseline lung function) conducted from 1971-2011 (final follow-up, December 2018).
      Exposures: Participants were categorized into mutually exclusive groups by baseline lung function. PRISm was defined as the ratio of forced expiratory volume in the first second to forced vital capacity (FEV1:FVC) greater than or equal to 0.70 and FEV1 less than 80% predicted; obstructive spirometry FEV1:FVC ratio of less than 0.70; and normal spirometry FEV1:FVC ratio greater than or equal to 0.7 and FEV1 greater than or equal to 80% predicted.
      Main Outcomes and Measures: Main outcomes were all-cause mortality, respiratory-related mortality, coronary heart disease (CHD)-related mortality, respiratory-related events (hospitalizations and mortality), and CHD-related events (hospitalizations and mortality) classified by adjudication or validated administrative criteria. Absolute risks were adjusted for age and smoking status. Poisson and Cox proportional hazards models comparing PRISm vs normal spirometry were adjusted for age, sex, race and ethnicity, education, body mass index, smoking status, cohort, and comorbidities.
      Results: Among all participants (mean [SD] age, 53.2 [15.8] years, 56.4% women, 48.5% never-smokers), 4582 (8.5%) had PRISm. The presence of PRISm relative to normal spirometry was significantly associated with obesity (prevalence, 48.3% vs 31.4%; prevalence ratio [PR], 1.68 [95% CI, 1.55-1.82]), underweight (prevalence, 1.4% vs 1.0%; PR, 2.20 [95% CI, 1.72-2.82]), female sex (prevalence, 60.3% vs 59.0%; PR, 1.07 [95% CI, 1.01-1.13]), and current smoking (prevalence, 25.2% vs 17.5%; PR, 1.33 [95% CI, 1.22-1.45]). PRISm, compared with normal spirometry, was significantly associated with greater all-cause mortality (29.6/1000 person-years vs 18.0/1000 person-years; difference, 11.6/1000 person-years [95% CI, 10.0-13.1]; adjusted hazard ratio [HR], 1.50 [95% CI, 1.42-1.59]), respiratory-related mortality (2.1/1000 person-years vs 1.0/1000 person-years; difference, 1.1/1000 person-years [95% CI, 0.7-1.6]; adjusted HR, 1.95 [95% CI, 1.54-2.48]), CHD-related mortality (5.4/1000 person-years vs 2.6/1000 person-years; difference, 2.7/1000 person-years [95% CI, 2.1-3.4]; adjusted HR, 1.55 [95% CI, 1.36-1.77]), respiratory-related events (12.2/1000 person-years vs 6.0/1000 person-years; difference, 6.2/1000 person-years [95% CI, 4.9-7.5]; adjusted HR, 1.90 [95% CI, 1.69-2.14]), and CHD-related events (11.7/1000 person-years vs 7.0/1000 person-years; difference, 4.7/1000 person-years [95% CI, 3.7-5.8]; adjusted HR, 1.30 [95% CI, 1.18-1.42]).
      Conclusions and Relevance: In a large, population-based sample of US adults, baseline PRISm, compared with normal spirometry, was associated with a small but statistically significant increased risk for mortality and adverse cardiovascular and respiratory outcomes. Further research is needed to explore whether this association is causal.
    • Comments:
      Erratum in: JAMA. 2022 Jan 18;327(3):286. (PMID: 35040903)
    • References:
      JAMA. 2019 Jun 25;321(24):2438-2447. (PMID: 31237643)
      JAMA Intern Med. 2020 May 1;180(5):676-686. (PMID: 32119036)
      BMJ. 2016 Sep 06;354:i4482. (PMID: 27599725)
      JAMA. 2016 Feb 16;315(7):672-81. (PMID: 26881370)
      Chest. 2012 Jan;141(1):87-93. (PMID: 21757568)
      Respir Res. 2014 Aug 06;15:89. (PMID: 25096860)
      Eur Respir J. 2015 Oct;46(4):1104-12. (PMID: 26113680)
      Respir Care. 2016 Sep;61(9):1192-200. (PMID: 27165420)
      Int J Tuberc Lung Dis. 2012 Oct;16(10):1405-11. (PMID: 22863565)
      Respir Res. 2013 Oct 09;14:103. (PMID: 24107140)
      Chest. 2013 May;143(5):1395-1406. (PMID: 23715520)
      Eur Respir J. 2020 Jan 2;55(1):. (PMID: 31601717)
      N Engl J Med. 2011 Mar 10;364(10):897-906. (PMID: 21388308)
      Multidiscip Respir Med. 2015 Feb 28;10(1):7. (PMID: 25745559)
      Eur Respir J. 2012 Dec;40(6):1324-43. (PMID: 22743675)
      Am J Respir Crit Care Med. 2018 Dec 1;198(11):1397-1405. (PMID: 29874098)
      J Am Heart Assoc. 2019 Feb 19;8(4):e011295. (PMID: 30776949)
      Am J Respir Crit Care Med. 2021 Oct 15;204(8):910-920. (PMID: 34233141)
      Kidney Int. 2005 Jun;67(6):2089-100. (PMID: 15882252)
      Thorax. 2014 Jan;69(1):55-62. (PMID: 23939399)
      Eur Respir J. 2017 May 25;49(5):. (PMID: 28546266)
      Am Fam Physician. 2014 Mar 1;89(5):359-66. (PMID: 24695507)
      ESC Heart Fail. 2018 Apr;5(2):364-371. (PMID: 29345431)
      Sci Rep. 2018 Oct 26;8(1):15900. (PMID: 30367154)
      Am J Respir Crit Care Med. 2006 Oct 1;174(7):810-6. (PMID: 16809633)
      BMC Pulm Med. 2014 Dec 22;14:208. (PMID: 25532602)
      Thorax. 2010 Jun;65(6):499-504. (PMID: 20522846)
      Thorax. 2003 May;58(5):388-93. (PMID: 12728157)
      Ann Am Thorac Soc. 2018 Oct;15(10):1186-1196. (PMID: 30011374)
      Am J Epidemiol. 2018 Nov 1;187(11):2265-2278. (PMID: 29982273)
      Am J Respir Crit Care Med. 1999 Jan;159(1):179-87. (PMID: 9872837)
      Eur Respir J. 2013 Oct;42(4):1046-54. (PMID: 23520323)
      N Engl J Med. 2010 Jul 22;363(4):321-30. (PMID: 20647190)
      Am J Kidney Dis. 2016 Sep;68(3):414-21. (PMID: 27130720)
      Ann Am Thorac Soc. 2016 Jul;13(7):1057-66. (PMID: 27088163)
      Circulation. 2017 Mar 7;135(10):e146-e603. (PMID: 28122885)
      Lancet Respir Med. 2020 Jan;8(1):34-44. (PMID: 31606435)
      Chest. 2006 Sep;130(3):827-33. (PMID: 16963682)
    • Grant Information:
      K23 HL133438 United States HL NHLBI NIH HHS; R01 ES021367 United States ES NIEHS NIH HHS; R01 AG023629 United States AG NIA NIH HHS; R01 HL109282 United States HL NHLBI NIH HHS; R01 HL109315 United States HL NHLBI NIH HHS; R01 HL109284 United States HL NHLBI NIH HHS; R01 HL090863 United States HL NHLBI NIH HHS; IK2 RX002165 United States RX RRD VA; U01 HL041642 United States HL NHLBI NIH HHS; R01 HL122477 United States HL NHLBI NIH HHS; R01 HL121270 United States HL NHLBI NIH HHS; U01 HL041654 United States HL NHLBI NIH HHS; R01 HL093081 United States HL NHLBI NIH HHS; R01 ES025216 United States ES NIEHS NIH HHS; U01 HL080295 United States HL NHLBI NIH HHS; R21 HL153700 United States HL NHLBI NIH HHS; R01 HL109319 United States HL NHLBI NIH HHS; R01 HL130506 United States HL NHLBI NIH HHS; U01 HL065521 United States HL NHLBI NIH HHS; R21 EB027891 United States EB NIBIB NIH HHS; R21 HL129924 United States HL NHLBI NIH HHS; U01 HL041652 United States HL NHLBI NIH HHS; U01 HL130114 United States HL NHLBI NIH HHS; R21 HL121457 United States HL NHLBI NIH HHS; R01 HL151421 United States HL NHLBI NIH HHS; K23 HL130627 United States HL NHLBI NIH HHS; U01 HL065520 United States HL NHLBI NIH HHS; R01 HL109301 United States HL NHLBI NIH HHS; R01 AG028050 United States AG NIA NIH HHS; R01 HL077612 United States HL NHLBI NIH HHS; R01 NR012459 United States NR NINR NIH HHS
    • Publication Date:
      Date Created: 20211214 Date Completed: 20220114 Latest Revision: 20240223
    • Publication Date:
      20240223
    • Accession Number:
      PMC8672237
    • Accession Number:
      10.1001/jama.2021.20939
    • Accession Number:
      34905031